An Interventional Open-Label Phase Ib/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in Combination with Different Anticancer Agents in Participants with Advanced Solid Tumors

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Yuanbin Chen, MD

Phase: I/II

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07227298

Objective

The purpose of this clinical trial is to evaluate the safety and tolerability of the study drugs when given together and to identify any dose-limiting side effects. The study will also assess early signs of anti-tumor activity (how well the treatment works against the cancer).

Share:

Related Clinical Trials

A Phase III Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 followed by a Randomized Controlled Trial of DFMO with or without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas
A Phase I/II Open-Label, Dose Escalation and Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-Guided T Cell Engaging Antibody that Targets STEAP2, in Adult Participants with Prostate Cancer (CRIUS-1)